A citation-based method for searching scientific literature

Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 856



Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn, William M Steinberg, Mette Stockner, Bernard Zinman, Richard M Bergenstal, John B Buse. N Engl J Med 2016
Times Cited: 2820




List of shared articles



Times cited


Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
Taufiq Salahuddin, Vanessa Richardson, Demetria M McNeal, Kamal Henderson, Paul L Hess, Sridharan Raghavan, David R Saxon, Javier A Valle, Stephen W Waldo, P Michael Ho,[...]. Diabetes Obes Metab 2021
0


The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes.
Francisco J Barrera, Freddy Jk Toloza, Oscar J Ponce, Jorge A Zuñiga-Hernandez, Larry J Prokop, Nilay D Shah, Gordon Guyatt, Rene Rodriguez-Gutierrez, Victor M Montori. Endocrine 2021
0




Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
1

Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.
Thomas A Zelniker, David A Morrow, Ofri Mosenzon, Erica L Goodrich, Petr Jarolim, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John Wilding,[...]. Eur J Heart Fail 2021
3


Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Chintan V Dave, Seoyoung C Kim, Allison B Goldfine, Robert J Glynn, Angela Tong, Elisabetta Patorno. Circulation 2021
3

Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.
Lin Wang, Yin Cai, Liguo Jian, Chi Wai Cheung, Liangqing Zhang, Zhengyuan Xia. Cardiovasc Diabetol 2021
2

Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives.
Alessandro Bellis, Ciro Mauro, Emanuele Barbato, Antonio Ceriello, Antonio Cittadini, Carmine Morisco. Int J Mol Sci 2021
1

Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Gábor Sütő, Gergő A Molnár, Gyorgy Rokszin, Ibolya Fábián, Zoltan Kiss, Zoltán Szekanecz, Gyula Poór, György Jermendy, Peter Kempler, István Wittmann. BMJ Open Diabetes Res Care 2021
2

Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Elisabetta Patorno, Ajinkya Pawar, Lily G Bessette, Dae H Kim, Chintan Dave, Robert J Glynn, Medha N Munshi, Sebastian Schneeweiss, Deborah J Wexler, Seoyoung C Kim. Diabetes Care 2021
3


Treatments for NAFLD: State of Art.
Alessandro Mantovani, Andrea Dalbeni. Int J Mol Sci 2021
3

Evolution and Outcomes of Premature Coronary Artery Disease.
Cara Lea Smith, Matthew Seigerman, Srinath Adusumalli, Jay Giri, Paul N Fiorilli, Daniel M Kolansky, Taisei Kobayashi. Curr Cardiol Rep 2021
0